85
Views
6
CrossRef citations to date
0
Altmetric
Review

Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia

&
Pages 757-765 | Published online: 18 Feb 2016

References

  • SiegelRLMillerKDJemalACancer statistics, 2015CA Cancer J Clin201565152925559415
  • SEER Cancer Statistics Review [webpage on the Internet]Previous Version: SEER Cancer Statistics Review, 1975–20102015 Available from: http://seer.cancer.gov/archive/csr/1975_2010/Accessed October 4, 2015
  • HungerSPLuXDevidasMImproved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology groupJ Clin Oncol201230141663166922412151
  • StockWJohnsonJLStoneRMDose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802Cancer20131191909822744771
  • ThomasDAO’BrienSFaderlSChemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemiaJ Clin Oncol201028243880388920660823
  • StillerCAChessellsJMFitchettMNeurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG studyBr J Cancer19947059699727947106
  • StrevensMJLilleymanJSWilliamsRBShwachman’s syndrome and acute lymphoblastic leukaemiaBr Med J19782612918277273
  • PassargeEBloom’s syndrome: the German experienceAnn Genet1991343–41791971809225
  • TaylorAMMetcalfeJAThickJMakYFLeukemia and lymphoma in ataxia telangiectasiaBlood19968724234388555463
  • De JongeRTissingWJEHooijbergJHPolymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemiaBlood2009113102284228919020309
  • PrestonDLKusumiSTomonagaMCancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950–1987Radiat Res19941372 supplS68S978127953
  • ErratumRadiat Res19941391129
  • GreavesMInfection, immune responses and the aetiology of childhood leukaemiaNat Rev Cancer20066319320316467884
  • CampoESwerdlowSHHarrisNLPileriSSteinHJaffeESThe 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applicationsBlood2011117195019503221300984
  • HoelzerDThielELöfflerHPrognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adultsBlood19887111231313422030
  • WetzlerMDodgeRKMrózekKProspective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experienceBlood199993113983399310339508
  • HoelzerDPersonalized medicine in adult acute lymphoblastic leukemiaHaematologica2015100785585826130512
  • CampanaDMinimal residual disease in acute lymphoblastic leukemiaHematol Hematology Am Soc Hematol Educ Program2010201071221239764
  • BassanRSpinelliOOldaniEImproved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)Blood2009113184153416219141862
  • LarsonRADodgeRKBurnsCPA five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811Blood1995858202520377718875
  • LinkerCALevittLJO’DonnellMFormanSJRiesCATreatment of adult acute lymphoblastic leukemia with intensive cyclical chemo-therapy: a follow-up reportBlood19917811281428221835410
  • KantarjianHThomasDO’BrienSLong-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemiaCancer2004101122788280115481055
  • SiveJIBuckGFieldingAOutcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trialBr J Haematol2012157446347122409379
  • HuguetFLeguayTRaffouxEPediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 studyJ Clin Oncol200927691191819124805
  • BleyerWAPoplackDGProphylaxis and treatment of leukemia in the central nervous system and other sanctuariesSemin Oncol19851221311483892694
  • CortesJO’BrienSMPierceSKeatingMJFreireichEJKantarjianHMThe value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemiaBlood1995866209120977662956
  • GökbugetNKnebaMRaffTGerman Multicenter Study Group for Adult Acute Lymphoblastic LeukemiaAdult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapiesBlood201212091868187622442346
  • LitzowMRFinally moving forward in adult ALLBlood2015125162453245425883226
  • GuptaVRichardsSRoweJAcute Leukemia Stem Cell Transplantation Trialists’ Collaborative Group. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysisBlood2013121233935023165481
  • FieldingAKRichardsSMChopraRMedical Research Council of the United Kingdom Adult ALL Working PartyEastern Cooperative Oncology GroupOutcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 studyBlood2007109394495017032921
  • GökbugetNStanzeDBeckJGerman Multicenter Study Group for Adult Acute Lymphoblastic LeukemiaOutcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantationBlood20121202032204122493293
  • TavernierEBoironJMHuguetFGET-LALA GroupSwiss Group for Clinical Cancer Research SAKKAustralasian Leukaemia and Lymphoma GroupOutcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trialLeukemia2007211907191417611565
  • KantarjianHGandhiVCortesJPhase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemiaBlood200310272379238612791647
  • AbbiKKSRybkaWEhmannWCClaxtonDFPhase I/II study of clofarabine, etoposide, and mitoxantrone in patients with refractory or relapsed acute leukemiaClin Lymphoma Myeloma Leuk2015151414625085441
  • Le JeuneCThomasXAntibody-based therapies in B-cell lineage acute lymphoblastic leukaemiaEur J Haematol2015949910824981395
  • GruppSAKalosMBarrettDChimeric antigen receptor-modified T cells for acute lymphoid leukemiaN Engl J Med2013368161509151823527958
  • KantarjianHThomasDWayneASO’BrienSMonoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemiaJ Clin Oncol201230313876388322891271
  • AiJAdvaniACurrent status of antibody therapy in ALLBr J Haematol2015168447148025382151
  • RaponiSDe ProprisMSIntoppaSFlow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 casesLeuk Lymphoma20115261098110721348573
  • FujimotoMPoeJCInaokiMTedderTFCD19 regulates B lymphocyte responses to transmembrane signalsSemin Immunol19981042672779695183
  • BarachoGVMileticAVOmoriSACatoMHRickertRCEmergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiationCurr Opin Immunol201123217818321277760
  • DreierTLorenczewskiGBrandlCExtremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibodyInt J Cancer2002100669069712209608
  • NagorsenDKuferPBaeuerlePABargouRBlinatumomab: a historical perspectivePharmacol Ther2012136333434222940266
  • NagorsenDBaeuerlePAImmunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomabExp Cell Res201131791255126021419116
  • OffnerSHofmeisterRRomaniukAKuferPBaeuerlePAInduction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cellsMol Immunol200643676377116360021
  • Blincyto® (blinatumomab) Available from: http://pi.amgen.com/united_states/blincyto/blincyto_pi_hcp_english.pdfAccessed October 11, 2015
  • WuBHijaziYWolfABrandlCSunYNZhuMPharmacokinetics (PK) of blinatumomab and its clinical implicationsJ Clin Oncol20133115 abstract 3048
  • KaplanJBGrischenkoMGilesFJBlinatumomab for the treatment of acute lymphoblastic leukemiaInvest New Drugs20153361271127926383529
  • BargouRLeoEZugmaierGTumor regression in cancer patients by very low doses of a T cell-engaging antibodyScience2008321589197497718703743
  • KlingerMBrandlCZugmaierGImmunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomabBlood2012119266226623322592608
  • ToppMSKuferPGökbugetNTargeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survivalJ Clin Oncol201129182493249821576633
  • ToppMSGökbugetNZugmaierGLong-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALLBlood2012120265185518723024237
  • GökbugetNDombretHBonifacioMBLAST: a confirmatory, single-arm, phase 2 study of blinatumomab, a bispecific T-cell engager (BiTE®) antibody construct, in patients with minimal residual disease B-precursor acute lymphoblastic leukemia (ALL)Poster presented at: American Society of Hematology (ASH) Annual MeetingDecember 6–9, 2014San Franscisco, CA Abstract 379
  • ToppMSGökbugetNZugmaierGPhase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemiaJ Clin Oncol201432364134414025385737
  • ToppMSGökbugetNSteinASSafety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 studyLancet Oncol2015161576625524800
  • SchlegelPLangPZugmaierGPediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomabHaematologica20149971212121924727818
  • RiberaJ-MFerrerARiberaJGenescàEProfile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemiaOnco Targets Ther201581567157426170691
  • BarrettDMTeacheyDTGruppSAToxicity management for patients receiving novel T-cell engaging therapiesCurr Opin Pediatr2014261434924362408
  • TeacheyDTRheingoldSRMaudeSLCytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapyBlood2013121265154515723678006
  • MartinelliGDombretHChevallierPComplete molecular and hematologic response in adult patients with relapsed/refractory (R/R) Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia (ALL) following treatment with blinatumomab: results from a phase 2 single-arm, multicenter study (ALCANTARA)Blood2015126issue 23 abstract 679
  • MaudeSLFreyNShawPAChimeric antigen receptor T cells for sustained remissions in leukemiaN Engl J Med2014371161507151725317870